No risk of Guillain–Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies

@article{Yih2012NoRO,
  title={No risk of Guillain–Barr{\'e} syndrome found after meningococcal conjugate vaccination in two large cohort studies},
  author={W Katherine Yih and Eric Weintraub and Martin Kulldorff},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2012},
  volume={21}
}
The large cohort study conducted by Dr. Velentgas and colleagues reported in this journal1 allayed concerns that had emerged in 2005 from the Vaccine Adverse Event Reporting System about a possible association between the meningococcal conjugate vaccine Menactra (MCV4) and Guillain–Barré syndrome (GBS) among adolescents.2 In an adolescent cohort comprising more than 1.4 million MCV4 vaccinations, no confirmed cases of GBS occurred in the 6weeks after vaccination. The upper bound of the one… Expand
Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
TLDR
The Vaccine Safety Datalink's Guillain Barré Syndrome surveillance following quadrivalent HPV vaccine from 2006 through 2015 found no evidence of an increased risk of GBS following 4vHPV. Expand
Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome.
TLDR
It is shown that an association between vaccine administration and GBS has never been proven for most of debated vaccines, although it cannot be definitively excluded and the benefits of vaccination are clearly demonstrated by the eradication or enormous decline in the incidence of many vaccine-preventable diseases. Expand
Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
TLDR
Incidences of Guillain-Barré Syndrome were in line with the range previously reported for young people, supporting the potential of BIFAP for performing studies on GBS, and a lack of power may be present for quantifying the relative risk of such a rare disease after the vaccination among the study cohort. Expand
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.
TLDR
This study provides reassurance that MenACWY-D administered as part of routine clinical care to patients at Kaiser Permanente Northern California was not associated with unexpected safety risks and did not detect any safety concerns following menactra® vaccine. Expand
Current safety issues with quadrivalent meningococcal conjugate vaccines
TLDR
The current state of knowledge with respect to the safety of quadrivalent meningococcal conjugate vaccines is described, and potential areas for safety research for these vaccines are identified. Expand
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
TLDR
Findings from a comprehensive review of reports to VAERS are consistent with data from pre-licensure studies and provide further reassurance on the safety of MenACWY-D. Expand
Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review
TLDR
Two quadrivalent meningococcal conjugate vaccines (MenACWY) that prevent invasive meningitis disease caused by N. meningitidis serogroups A, C, Y, and W have been licensed in the U.S. in the past 10–15 years and a post-licensure safety evaluation found no new significant safety concerns related to the product. Expand
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
TLDR
Routine use of a MenB series for adolescents and young adults aged 16–23 years on the basis of shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis is recommended. Expand
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.
TLDR
Immunization of infants and young children with MenACWY-D vaccine was not associated with any new safety concerns; however, these small studies had limited power to detect rare or uncommon safety events. Expand
Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes?
TLDR
No definitive demonstration of a potential role of vaccines in causing autoimmune neurological syndromes is presently available, so the fear of neurological autoimmune disease cannot limit the use of the most important preventive measure presently available against infectious diseases. Expand
...
1
2
...

References

SHOWING 1-7 OF 7 REFERENCES
Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination
TLDR
A study was conducted to assess the risk of Guillain–Barré syndrome after MCV4 vaccination using health plan administrative and claims data together with the review of primary medical records of potential cases. Expand
Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.
  • Medicine
  • MMWR. Morbidity and mortality weekly report
  • 2005
TLDR
Routine vaccination of adolescents at the preadolescent health-care visit and for first-year college students living in dormitories and for other persons at increased risk are recommended. Expand
Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events
TLDR
Real-time surveillance combining dynamic data files, aggregation of data, and sequential analysis methods offers a useful and highly adaptable approach to early detection of adverse events after the introduction of new vaccines. Expand
Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States
  • MMWR Morb Mortal Wkly Rep
Harvard Pilgrim Health Care Institute and Harvard Medical School
    Harvard Pilgrim Health Care Institute, and Harvard Medical School E-mail